Appendix Table C15. Survival and local control outcomes of studies that address Key Question 3

| Study | Survival Outcomes for Intervention Group 1 | Survival Outcomes for Intervention Group 2 | Local Control Outcomes for Intervention Group 1 | Local Control Outcomes for Intervention Group 2 | Arm |
| --- | --- | --- | --- | --- | --- |
| Allison-2004, #108 | **Overall survival:** 10.3 months (±4.1) (calculated)**Cancer/disease specific survival:**Not reported | **Overall survival:**NA**Cancer/disease specific survival:** NA  | **Local control:**100 %. No patient had local recurrence till they all died. However, mean or median FU time not reported. | **Local control:**NA | No |
| Chella-2000, #654 | YAGL + BCHY**Overall survival:** Median survival: 10.3 months (method Not reported)**Cancer/disease specific survival:**Not reported | YAGL**Overall survival:**Median survival: 7.4 months (method Not reported)**Cancer/disease specific survival:** Not reported | YAGL + BCHY**Local control:**Not reported | YAGL**Local control:**Not reported | No |
| Celebioglu-2002, #604 | **Overall survival:** Not reported**Cancer/disease specific survival:**Not reported | **Overall survival:**NA**Cancer/disease specific survival:** NA | **Local control:**Not reported | **Local control:**NA | No |
| Celikoglu-2006, #606 | **Overall survival:** Not reported**Cancer/disease specific survival:**Not reported | **Overall survival:**NA**Cancer/disease specific survival:** NA | **Local control:**Not reported | **Local control:**Not reported | No |
| Chhajed-2006, #696 | STNT or LASR:**Overall survival:** Median survival : 8.4 months (4.8-17.1), 3-months survival: 90%6-months survival: 71%12-months survival: 40%**Cancer/disease specific survival:**Not reported | **Overall survival:** NA**Cancer/disease specific survival:** NA | **Local control:**9 patients had tumor growth. Thus local control was 87% (at unspecified time, assumption at the time of study closeout, average FU period not given)  | **Local control:**NA | Yes |
| Guilcher-2011, #188 | **Overall survival:** Median survival: 28.6 months2 yr: 57%5 yr: 29% **Cancer/disease specific survival:**2 yr: 81%5 yr: 56%  | **Overall survival:**NA**Cancer/disease specific survival:** NA | **Local control:**G3data | **Local control:**NA | No |
| Jimenez-1999, #978 | PHDT:**Overall survival:** Median survival:265 days**Cancer/disease specific survival:**Not reported | YAGL:**Overall survival:**Median survival 95 days (p=0.007)**Cancer/disease specific survival:** Not reported  | PHDT:**Local control:**Not reported | YAGL:**Local control:**Not reported | No |
| Jones-2001, ,#1862 | **Overall survival:** Mean survival:From diagnosis: 10.5 monthsPost PHDT Rx: 5.5 months**Cancer/disease specific survival:**Not reported | **Overall survival:**NA**Cancer/disease specific survival:** NA | **Local control:**Not reported | **Local control:**NA | No |
| Langendjik-2001, #2144 | EBRT +BCHY: **Overall survival:** Median survival: 7.0 months (95%CI: 5.3 to 8.9)**Cancer/disease specific survival:**Not reported | EBRT: **Overall survival:**Median survival: 8.5 months (95%CI: 5.4 to 11.6)**Cancer/disease specific survival:**Not reported  | EBRT +BCHY: **Local control:**Not reported | EBRT: **Local control:**Not reported | No |
| Lencioni-2008, #2238 | **Overall survival:** 1 yr: 70% (95% CI: 51 to 83) 2 yr: 48% (95% CI: 30 to 65) **Cancer/disease specific survival:**1 yr: 92% (95% CI: 78–98) 2 yr: 73% (95% CI: 54–86)  | **Overall survival:**NA**Cancer/disease specific survival:** NA | **Local control:**Not reported | **Local control:**NA | Yes |
| Moghissi-1999, #2591 | EBRT:**Overall survival:** Median survival: 182 days1 yr survival: 26%**Cancer/disease specific survival:**Not reported | EBHT:**Overall survival:**Median survival: 150 days1 yr survival: 29%**Cancer/disease specific survival:** Not reported | **Local control:**Not reported | **Local control:**Not reported | No |
| Muto-2000, Italy, #2665 | **Overall survival:** Mean survival from diagnosis: 11.1 monthsMean survival from last HDR BCHY Rx: 9.7 months**Cancer/disease specific survival:**Not reported | **Overall survival:**NA**Cancer/disease specific survival:** NA | **Local control:**Not reported | **Local control:**NA | No |
| Mallick-2006, #2417 | **Overall survival:** Not reported**Cancer/disease specific survival:** Not reported | **Overall survival:** Not reported**Cancer/disease specific survival:** Not reported | **Local control:** Not reported | **Local control:** Not reported | No |
| Petera-2001, #2914 | **Overall survival:** Median survival (from diagnosis)BCHY (Cur): 365 days (92-670)BCHY (Pall): 242 days (30-881)Median survival ( 1st BCHY Rx)BCHY (Cur): 245 days (1-396)BCHY (Pall): 242 days (1-850)**Cancer/disease specific survival:**Not reported | **Overall survival:**NA**Cancer/disease specific survival:** Not reported | **Local control:**Not reported | **Local control:**NA | Yes |
| Stout-2000, #3640 | BCHY: **Overall survival:** Median: 250 days1 yr: 22%2 yr: 2%**Cancer/disease specific survival:**Not reported | EBRT:**Overall survival:**Median: 287 days (p=0.042)1 yr: 38%2 yr: 10%**Cancer/disease specific survival:**Not reported | **Local control:**Not reported | **Local control:**Not reported | No |
| van Boxem-1999, #427 | **Overall survival:** YAGL: 8.0 ± 2.5 m**Cancer/disease specific survival:**Not reported | **Overall survival:**ECAU: 11.5 ± 3.5 m**Cancer/disease specific survival:** Not reported | **Local control:**Not reported | **Local control:**Not reported | No |
| Vucicevic-1999, #4010 | **Overall survival:** G3 dataFig 5 page 380**Cancer/disease specific survival:**Not reported | **Overall survival:**NA**Cancer/disease specific survival:** NA | **Local control:**Not reported | **Local control:**NA | No |
| Weinberg-2010, #4066 | **Overall survival:** Consult TR Page 54 table 2**Cancer/disease specific survival:**Not reported | **Overall survival:**NA**Cancer/disease specific survival:** NA | **Local control:**Not reported | **Local control:**NA | No |